



September 2023

Dear Alice,

We hope you've had a great summer! We're pleased to welcome you to the autumn edition of the **Blood Cancer UK Clinical Trials Support Service** Newsletter.

Thanks to all of you who let us know what you'd like to call this newsletter and the service we provide to people like yourself interested in trials for the future.

And the winner is: **The Clinical Trials Patient Registry** (or CTPR for short)

Over the coming months we'll be developing an area of our website with more dedicated content for you in addition to this newsletter. More on that in a later edition.

We've some great stories for you this month, and, as ever, if you've anything you'd like us to cover or have any questions, please get in touch.

Happy reading!

Jane, Rachel, Lynne and Elizabeth
The CTSS Team

"Say Blood Cancer"

September is Blood Cancer Awareness Month and this year we're asking people to 'Say Blood Cancer'.

You can read more about the work we're doing to raise the profile of blood cancer and hear stories from our community. This year we've got a celebrity friend to front our campaign.

[Find out more here](#)



Omaze-ing news!



Blood Cancer UK first partnered with Omaze back in 2021 when £1 million was raised to fund research into improved treatment. In July 2023 we joined forces again and almost doubled that amount.

[Read more about Omaze](#)

Vaccination update

Starting from 1 September 2023, people over 50 who are immunocompromised will be eligible for the new non-live Shingrix vaccine as an alternative to the previous standard live shingles vaccine.

Autumn Covid boosters are also being rolled out from this month.

Read the latest information here:

Shingles

Covid



Meet Rachel



This month Rachel tells us about how she came across the Clinical Trials Support Service after posting on the Blood Cancer UK Forum.

[Read what happened next](#)

Trial updates

You may have recently seen news out of the Christie Hospital in Manchester about positive results, including reduced side effects being seen in trials using immunotherapy for myeloma.

[Independent article](#)

Findings from inobrodib trials for relapsed or refractory myeloma patients have been so positive that the FDA, the agency which approves treatments in the USA, have fast tracked approval.

[Inobrodib designation](#)

Interested in being part of research?

While a clinical trial might not be available for you right now, there are other ways to be involved in research.

CICERO is a study at the University of Oxford exploring how patients prefer the risks and benefits of treatment to be communicated - completely in words, mostly words with some pictures, or a mix of both. If you're interested, find out more.

CICERO

The **NIHR People in Research** webpage lists several opportunities to be involved in different ways - from being on advisory groups, to co-designing studies, exploring improved recruitment to clinical trials and more!

People in Research

Do let us know if you decide to take part in any of these studies or are interested in another area of trial development and support.

Keeping in touch

Remember, if there's anything in the newsletter you'd like to ask about, if you have any questions or want to talk through any clinical trial options, we're always here for you. Just drop us a line at trials@bloodcancer.org.uk and if you'd prefer we can arrange a phone or zoom call at a time to suit.

Because together we can be the generation to beat blood cancer

Donate Now



Registered with
**FUNDRAISING
REGULATOR**

Need to talk about blood cancer? Call our support line free on 0808 2080 888

Blood Cancer UK is the trading name of Bloodwise, registered address: Bloodwise, 5-11 Theobalds Road, London, WC1X 8SH. Correspondence address: Suite 31 Bonnington Bond, 2 Anderson Place, Edinburgh, EH6 5NP. A company limited by guarantee 738089 (registered in England and Wales). Registered charity 216032 (England and Wales) SC037529 (Scotland) © 2022

[Unsubscribe](#) | [Privacy policy](#)

Blood Cancer UK is committed to ensuring your privacy. For full details on how we look after your data, please read our [Privacy Policy](#). You can change your preferences at any time by calling us on **0808 2080 888**, email to hello@bloodcancer.org.uk, or you can write to us at

Suite 31 Bonnington Bond, 2 Anderson Place, Edinburgh, EH6 5NP